Plasma-Derived Human C1 Inhibitor (pdhC1INH) is the Appropriate Tissue Enzyme During Pregnancy and Lactation
Plasma-derived human C1 inhibitor (pdhC1INH) appears to be safe and effective during both pregnancy and lactation for either prophylaxis or acute therapy, making it the tissue-derived proteolytic enzyme of choice in these populations 1.
Evidence-Based Recommendation
The international consensus guidelines from the Journal of Allergy and Clinical Immunology (2012) provide clear guidance on tissue enzyme use during pregnancy and lactation, specifically addressing pdhC1INH:
During Pregnancy
- pdhC1INH is the first-line treatment for both long-term prophylaxis (LTP) and acute therapy in pregnant women 1
- No controlled studies with pregnant women have been conducted, but extensive clinical experience demonstrates safety and efficacy 1
- Side effects are rare 1
- The medication dosage remains the same regardless of pregnancy status 1
During Lactation
- pdhC1INH is safe and effective during breastfeeding for both prophylactic and acute treatment 1
- Women can continue breastfeeding while receiving pdhC1INH therapy
Alternative Options (When pdhC1INH is Unavailable)
If pdhC1INH is not available, the guidelines provide a clear hierarchy:
Second-Line: Virally Inactivated Fresh Frozen Plasma (viFFP)
- Can serve as an alternative for long-term prophylaxis (evidence level III) 1
- Can be administered for acute attacks 1
- Caution: Risk of worsening symptoms due to substrate supply before C1-INH acts 1
Third-Line: Antifibrinolytics (Tranexamic Acid)
- Only when pdhC1INH is unavailable (evidence level III) 1
- Animal studies show no teratogenic effects, but human teratogenic risk studies lacking 1
- Usually administered during second half of pregnancy 1
- Can be used for mild edema attacks 1
Contraindicated Tissue Enzymes
Anabolic Androgens (AAs) are absolutely contraindicated during pregnancy, particularly in the first trimester 1:
- Cross the placenta and affect fetal development
- Can cause virilization of female fetuses
- May cause placental insufficiency and fetal growth retardation 1
Clinical Context
The question appears to reference tissue-derived proteolytic enzymes in the context of hereditary angioedema (HAE-C1-INH) management, where C1 inhibitor replacement is the cornerstone of therapy. While other research discusses various proteolytic enzymes in pregnancy (plasminogen activators, matrix metalloproteases), these are endogenous enzymes studied in physiological contexts 2, 3, not therapeutic agents appropriate for clinical use.
The evidence is unequivocal: pdhC1INH is the tissue enzyme of choice during pregnancy and lactation, with a well-established safety profile and clinical efficacy 1.